Highlights @eular_org #EULAR2025 RCTs + in CTD/RA #ILD w #PPF LB0003 Lots of #CAR-T studies in #SARDs Lots of bDMARDs in #SLE #APS #IgG4 #SjD Neurostimulation 👇 ⬇️inflammation ⬇️pain #RA #fibromyalgia #EULAR2025 @RheumNow @eular_org

Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA? 🔹️245 pts 🔹️CRP recorded for past 5y 🔹️sustained high CRP in 40% 🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis POS0714 #EULAR2025 @RheumNow https://t.co/jAlj3sr95H

• https://x.com/Nellziade/status/1933750084845355072/photo/1

Management of AAV: 1.High dose GC f/b reduced dose taper ‼️caution in pts w/severe renal dz and RTX induction. 2. RTX effective for induction and maintenance, best for relapses. 3.PLEX: in RPGN pts if accesible ⚠️ risk for infection. 4.Avacopan: for faster GC weaning. No https://t.co/kfZ4gM38KG

• https://x.com/AdelaCastro222/status/1933766189072687235/photo/1
• https://x.com/AdelaCastro222/status/1933766189072687235/photo/1
• https://x.com/AdelaCastro222/status/1933766189072687235/photo/1
• https://x.com/AdelaCastro222/status/1933766189072687235/photo/1

Pearls on EGPA: 1. GC are mainstay for mild dz 2. Organ threatening/relapsing➡️CYP (RTX alternative) 3. W/o organ threatening➡️ anti-IL-5/IL-5R. 4. IL5i are less effective for ENT 5. Consider sx for nasal polyps. #EULAR2025 @RheumNow https://t.co/zoJEWxafsN

• https://x.com/AdelaCastro222/status/1933768201017434618/photo/1
• https://x.com/AdelaCastro222/status/1933768201017434618/photo/1
• https://x.com/AdelaCastro222/status/1933768201017434618/photo/1
• https://x.com/AdelaCastro222/status/1933768201017434618/photo/1

EULAR FMF recommendations 2025: still emphasis on colchicine adherence to maximal dose +/- bDMARDs if needed for control +/- csDMARDs for residual chronic MSK involvement new: consider tapering bDMARD if remission >6mo See the treatment algorithm below⬇️ #EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL

• https://x.com/drdavidliew/status/1933786027857998292/photo/1
• https://x.com/drdavidliew/status/1933786027857998292/photo/1

Key summary slide of research in the use of CD19 CAR T cells in rheumatology indications Dinesh Khanna @RheumNow #EULAR2025 https://t.co/CoFHqaE1L1

• https://x.com/synovialjoints/status/1933786800495210968/photo/1

Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease. Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome ⬇️ see the next tweet #EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx

• https://x.com/drdavidliew/status/1933787645714284592/photo/1
• https://x.com/drdavidliew/status/1933787645714284592/photo/1
• https://x.com/drdavidliew/status/1933787645714284592/photo/1

FMF #Recommendations 🔺️Start Colchicine in All (& continue for confirmed pts) 🔺️Single or divided dose, depend on adherence & tolerance 🔺️Max dose 2 mg children, 3 mg adults 🔺️if failure: add IL1i (6 RCT) (2 for IL6i) 🔺️Add c or bDMARd if MSK #EULAR2025 @RheumNow https://t.co/fPyQrLbb6S

• https://x.com/Nellziade/status/1933787923419189744/photo/1

FMF #Recommendations During attack: 🔺️No use of increasing Colchicine 🔺️No use for corticosteroids and opioid 🔺️Use NSAIDs #EULAR2025 @RheumNow https://t.co/jJjWJra7yr

• https://x.com/Nellziade/status/1933787923851457020/photo/1

Autologous CAR T cell production, administration and monitoring Dinesh Khanna @RheumNow #EULAR2025 https://t.co/zrXjxSCRgl

• https://x.com/synovialjoints/status/1933787992759599579/photo/1

EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome 🔺️Do not apply if patient is positive for other antibodies like SSA #EULAR2025 @RheumNow https://t.co/AD5tTipBtt

• https://x.com/Nellziade/status/1933789191764119789/photo/1

FMF #Recommendations #Colchicine can be fatal 🔺️Monitor regularly #EULAR2025 @RheumNow https://t.co/VJZYPaBrvE

• https://x.com/Nellziade/status/1933789626692509988/photo/1

Why do people not respond to psoriatic arthritis therapies? #EULAR2025 @RheumNow https://t.co/VGLN0R3TyY

• https://x.com/drdavidliew/status/1933791747634835900/photo/1

What is the difference between difficult to treat, and treatment-refractory? (see these criteria for PsA) Treatment refractory means that co-morbidities, psychosocial issues and other factors have been managed adequately, but inflammation keeps on going #EULAR2025 @RheumNow https://t.co/Fzpf0eiCWY

• https://x.com/drdavidliew/status/1933793898075140152/photo/1

FMF #Recommendations #Colchicine can be fatal 🔺️Beware of drug interactions 🔺️Mostly statins in adults 🔺️Macrolides in children #EULAR2025 @RheumNow https://t.co/SYGLpAJXFu

• https://x.com/Nellziade/status/1933794041214148656/photo/1